key: cord-0074652-pxgoav4p
authors: Kucharczak, J; Garcia, V; Jolley, R; Mahajan, S; Auturally, R; Thomas, S; Besser, M
title: P136: THE UPTAKE OF VACCINATIONS IN ADULTS WITH SICKLE CELL DISEASE RECEIVING CARE AT THE CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST
date: 2022-01-31
journal: Hemasphere
DOI: 10.1097/01.hs9.0000821636.52063.c0
sha: 7a7d08e8daa3bd1365a2ababb71b7906581809ee
doc_id: 74652
cord_uid: pxgoav4p

nan

Those affected by sickle cell disease have an increased susceptibility to infection by encapsulated bacteria and hepatitis B virus due to reduced splenic function and increased likelihood of receiving blood transfusions. Sickle cell disease patients are also more likely to suffer from complications, such as vaso-occlusive crises or acute chest syndrome, following infection with influenza or COVID-19. Standards for Clinical Care of Adults with Sickle Cell Disease in the UK (2018) outline that that those with sickle cell disease are recommended to be vaccinated against invasive pneumococcal disease, Haemophilus influenza type B, Neisseria meningitis types ACWY and type B, hepatitis B, and influenza. These patients are also recommended to have their hepatitis B immunity reviewed annually and to receive a hepatitis B vaccination booster if hepatitis B surface antibody (HBsAb) levels are less than 100mIU/ml. According to the Standards, hospital staff is advised to remind and check with the patients' primary care teams whether these vaccinations have been administered. In this audit, we examined the records of 64 patients with sickle cell disease who receive regular care at the Cambridge University Hospitals NHS Foundation Trust. We collected data on the uptake of the pneumococcal conjugate vaccine (PCV13), pneumococcal polysaccharide vaccine (PPV23 or Pneumovax) within 5 years, two doses of Meningitis B vaccine, Meningitis ACWY vaccine (MenACWY), Haemophilus influenzae type b vaccine (Hib/MenC), influenza vaccine within one year, hepatitis B vaccine (HepB), whether HBsAb levels have been reviewed within one year, HepB booster if HBsAb levels were less than 100mIU/ml, and two doses of COVID-19 vaccine. These records were obtained from electrical medical records provided by patients' general practitioners. Data for the second dose of the COVID-19 vaccine. 43.8% had their HbsAB reviewed and 20.0% received a HepB booster following HBsAb levels of less than 100mIU/ml. The uptake levels for the recommended vaccinations are lower than expected in our hospital trust. The COVID-19 pandemic has highlighted the effect of health inequalities and the uptake of the vaccination programme by patients of different ethnicities. During our patient support group, patients identified the Tuskegee syphilis experiment as one of the reasons why there is still distrust of the medical profession by those with Afro-Caribbean heritage. Beyond directed patient education, more communication is needed with the primary care teams to raise awareness of which vaccinations are required for sickle cell patients. Certain vaccinations, such as MenACWY and MenB were only introduced in 2015, meaning that some general practitioners may be still unaware of their necessity in adults with sickle cell disease. , and highlighted as a "Top 10" Priority in a workshop during ASCAT 2019. In response, we conducted a series of workshops to explore how race and racism impacts the quality of care in the SCD community and to identify actionable areas of change. This comprised three 90 minute sessions held over Zoom in May, June and July 2021. Attendees included people living with SCD, doctors, nurses, medical students, and members of the local community.

Outcomes broadly centred around the themes of medical education; public education; and ways of better supporting the SCD patient community. However, we were struck by a rich discussion on how the name 'Sickle Cell Disease' may, in itself, influence the mindset of caregivers and perpetuate stigma in both clinical and social settings. The term 'Sickle Cell Anaemia' traditionally refers to HbSS only, though OMIM uses it to cover all genotypes [ 2 ] . Meanwhile the ICD-10 classification code D57 refers to 'Sickle Cell Disorders', with sub-categories using 'Disease' and divided by genotype [ 3 ] .From the workshops, the patient group shared a strong consensus view that Sickle Cell Disorder, rather than 'Disease', would be preferable as a more neutral term of reference.

To verify the results of the workshop in an independent sample, a questionnaire was circulated to a small SCD patient support group (12 individuals) to assess their preference for one or other label. 9/12 (75%) preferred 'Disorder', one preferred 'Disease' and two expressed no preference. Which label was used by patients themselves, their families and friends, and their medical teams was important to patients, with 67% expressing a wish that this issue be pursued further. Interestingly, the acceptability of Disorder/Disease showed some variation by the patient's country of birth. These findings point towards a pressing need for increased sensitivity around the language used to talk about illness, particularly where the condition has been historically stigmatised.

Medical science must address health disparities amongst different ethnic groups. Nat Hum Behav

MIM Number: 603903: 03/08/2021:. World Wide Web URL

World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. World Health Organization